Skip to main content

Abstract

A patient’s blood type can dictate availability of blood products necessary for treatment. Solve it!

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–81.

    Article  CAS  PubMed  Google Scholar 

  2. SOLIRIS®. Prescribing information. Boston, MA: Alexion Pharmaceuticals; 2020.

    Google Scholar 

  3. ULTOMIRIS®. Prescribing information. Boston, MA: Alexion Pharmaceuticals; 2020.

    Google Scholar 

  4. Wynick C, Britto J, Sawler D, Parker A, Karkhaneh M, Goodyear D, Sun HL. Validation of the PLASMIC score for predicting ADAMTS13 activity < 10% in patients admitted to hospitals in Alberta with suspected thrombotic thrombocytopenic purpura. Blood. 2019;134(Suppl 1):2379.

    Article  Google Scholar 

  5. Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34(323):324.

    Google Scholar 

  6. George JN. How I treat patient with thrombotic thrombocytopenic purpura: 2010. Blood. 2010;116(20):4060–9.

    Article  CAS  PubMed  Google Scholar 

  7. Louie J, Boctor F, Chiang J, Anwar Z, Wittenberg A, Gogas E. Efficacy of 5% albumin and fresh frozen plasma (AFFP) versus fresh frozen plasma (FFP) only as replacement fluid in plasma exchange for thrombotic thrombocytopenic purpura (TTP). Blood. 2012;120(21):272.

    Article  Google Scholar 

  8. Scully M, Cataland S, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335–46.

    Article  CAS  PubMed  Google Scholar 

  9. CABLIVI®. Prescribing information. Ghent, Belgium: Ablynx N.V; 2020.

    Google Scholar 

Further Reading

  • Webb J, Andrzejewski C. Therapeutic apheresis. In: Cohn CS, Delaney M, Johnson ST, Katz LM, editors. Technical manual. 20th ed. Bethesda: AABB; 2020. p. 705–29.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark T. Friedman .

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Friedman, M.T., West, K.A., Bizargity, P., Annen, K., Gur, H.D., Hilbert, T. (2023). Absolutely Necessary!. In: Immunohematology, Transfusion Medicine, Hemostasis, and Cellular Therapy. Springer, Cham. https://doi.org/10.1007/978-3-031-14638-1_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-14638-1_35

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-14637-4

  • Online ISBN: 978-3-031-14638-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics